{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:03:07Z","timestamp":1784782987776,"version":"3.55.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Gastroenterol."],"abstract":"\n Background<\/jats:title>\n Crohn\u2019s disease (CD) is a chronic inflammatory condition that affects the gastrointestinal tract. Currently, the diagnosis of CD is predominantly dependent on endoscopic procedures and histopathological tissue analysis. Endoscopy is an invasive procedure, patient compliance is poor, and the results are subject to the operator\u2019s subjective judgment. Infliximab (IFX) and ustekinumab (UST) are two new biologics used for the treatment of CD, which are effective in reducing inflammatory markers. However, the correlation between blood metabolites and inflammatory markers has rarely been studied in the biologic agents employed in the management of CD, and their effects on metabolic processes remain inadequately understood. This study aimed to elucidate the effects of IFX and UST on the blood metabolites in patients with CD, investigate the correlations between metabolic variations and clinical indicators, and examine the relationship between the identified biomarkers and clinical efficacy.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A total of 81 patients with CD who were receiving biologic therapy enrolled at week\u00a016 between January 2022 and December 2023 (45 receiving IFX and 36 receiving UST) and 45 healthy controls were included. Metabolite profiling was performed using high-performance liquid chromatography\u2013tandem mass spectrometry, followed by multivariate statistical and pathway enrichment analyses to identify differential metabolites and their correlations with clinical indicators.<\/jats:p>\n <\/jats:sec>\n \n Result<\/jats:title>\n \n Despite achieving clinical remission, both the IFX and UST groups exhibited significantly elevated C-reactive protein levels and erythrocyte sedimentation rate values compared with the control group (\n p<\/jats:italic>\n \u00a0&lt;\u00a00.05). IFX primarily influenced amino acid metabolism, including pathways involving arginine and glutamine, and glycolysis and the tricarboxylic acid cycle. UST impacted glutathione and purine metabolism. Pearson\u2019s correlation analysis demonstrated that\n l<\/jats:sc>\n -arginine,\n l<\/jats:sc>\n -glutamine, and\n l<\/jats:sc>\n -lysine were significantly negatively correlated with C-reactive protein. In the UST group, glutathione, adenosine, and hypoxanthine were primarily significantly negatively correlated with C-reactive protein and absolute lymphocyte count (\n p<\/jats:italic>\n \u00a0&lt;\u00a00.05).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n We identified two sets of diagnostic biomarkers: the biomarkers for the IFX group were\n l<\/jats:sc>\n -arginine,\n l<\/jats:sc>\n -glutamine, and\n l<\/jats:sc>\n -lysine, while those for the UST group were glutathione and adenosine.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fgstr.2026.1867424","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:28:13Z","timestamp":1784780893000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical study on the screening of biomarkers for Crohn\u2019s disease based on blood metabolomics"],"prefix":"10.3389","volume":"5","author":[{"given":"Tongyuan","family":"Lin","sequence":"first","affiliation":[{"name":"The Department of Gastroenterology, The First People\u2019s Hospital of Wu Hu","place":["Wuhu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhong","family":"Hu","sequence":"additional","affiliation":[{"name":"Postgraduate School, Anhui Normal University","place":["Wuhu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifei","family":"Yuan","sequence":"additional","affiliation":[{"name":"Postgraduate School, Anhui Normal University","place":["Wuhu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SiYuan","family":"Li","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First People\u2019s Hospital of Wu Hu","place":["Wuhu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lin","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First People\u2019s Hospital of Wu Hu","place":["Wuhu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First People\u2019s Hospital of Wu Hu","place":["Wuhu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cui","sequence":"additional","affiliation":[{"name":"The Department of Science and Education Section, The First People\u2019s Hospital of Wu Hu","place":["Wuhu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuanYuan","family":"Wang","sequence":"additional","affiliation":[{"name":"The Department of Science and Education Section, The First People\u2019s Hospital of Wu Hu","place":["Wuhu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First People\u2019s Hospital of Wu Hu","place":["Wuhu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First People\u2019s Hospital of Wu Hu","place":["Wuhu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01089-3","article-title":"The role of epigenetic modifications for the pathogenesis of Crohn's disease","volume":"13","author":"Hornschuh","year":"2021","journal-title":"Clin Epigenet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01008-6","article-title":"Strategies for targeting cytokines in inflammatory bowel disease","volume":"24","author":"Neurath","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.01.007","article-title":"The FOXP3+ pro-inflammatory T cell: a potential therapeutic target in Crohn's disease","volume":"166","author":"Kosinsky","year":"2024","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900710","article-title":"Dendritic cell subsets in intestinal immunity and inflammation","volume":"204","author":"Sun","year":"2020","journal-title":"J Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910273","article-title":"Tumor necrosis factor's pathway in Crohn's disease: potential for intervention","volume":"22","author":"Pagnini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000471","article-title":"Pharmacogenetic analysis of canonical versus noncanonical pathway of NF-kB in Crohn's disease patients under anti-tumor necrosis factor-\u03b1 treatment","volume":"32","author":"Stavrou","year":"2022","journal-title":"Pharmacogenet Genomics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3760\/cma.j.cn101480-20210702-00052","article-title":"Consensus on biological agents in treating patients with inflammatory bowel disease","volume":"5","author":"Chen","year":"2021"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/697832","article-title":"CRP and TNF-\u03b1\u2009\u2009induce PAPP-A expression in human peripheral blood mononuclear cells","volume":"2012","author":"Li","year":"2012","journal-title":"Mediators Inflammation"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18354","article-title":"Subcutaneous infliximab concentration thresholds for mucosal and transmural healing in patients with Crohn's disease","volume":"61","author":"Hong","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.622934","article-title":"Role of the IL23\/IL17 pathway in Crohn's disease","volume":"12","author":"Schmitt","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e30903","article-title":"LC-MS-based rheumatoid arthritis serum metabolomics reveals the role of deoxyinosine in attenuating collagen-induced arthritis in mice","volume":"10","author":"Xu","year":"2024","journal-title":"Heliyon"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030893","article-title":"Amino acid-metabolizing enzymes in advanced high-grade serous ovarian cancer patients: value of ascites as biomarker source and role for IL4I1 and IDO1","volume":"15","author":"Grobben","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2008.05.001","article-title":"Microinflammation in patients with Crohn's disease in clinical remission","volume":"2","author":"Maharshak","year":"2008","journal-title":"J Crohns Colitis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa054","article-title":"Distribution and cytokine profile of peripheral B cell subsets is perturbed in pediatric IBD and partially restored during a successful IFX therapy","volume":"27","author":"Schnell","year":"2021","journal-title":"Inflammation Bowel Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s12328-022-01731-4","article-title":"Immune-related colitis and pancreatitis treated with infliximab","volume":"16","author":"Ohwada","year":"2023","journal-title":"Clin J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215181","article-title":"Infliximab for treatment of immune adverse events and its impact on tumor response","volume":"15","author":"Parvathareddy","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.08.014","article-title":"Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease","volume":"106","author":"Maier","year":"2012","journal-title":"Respir Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2011.577093","article-title":"Interleukin-23: a key cytokine in inflammatory diseases","volume":"43","author":"Duvallet","year":"2011","journal-title":"Ann Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000437106","article-title":"The IL-12\/23\/STAT axis as a therapeutic target in inflammatory bowel disease: mechanisms and evidence in man","volume":"33","author":"Marafini","year":"2015","journal-title":"Dig Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.06.018","article-title":"Nitric oxide modulates metabolic remodeling in inflammatory macrophages through TCA cycle regulation and itaconate accumulation","volume":"28","author":"Bailey","year":"2019","journal-title":"Cell Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33502","article-title":"Derivation of novel metabolic pathway score identifies alanine metabolism as a targetable influencer of TNF-alpha signaling","volume":"10","author":"D'Souza","year":"2024","journal-title":"Heliyon"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116424","article-title":"Prediction of early remission after infliximab in Crohn's disease using baseline microbiome and metabolomics","volume":"251","author":"Guo","year":"2024","journal-title":"J Pharm BioMed Anal"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2025.156933","article-title":"The role of TNF in metabolic disorders and liver diseases","volume":"190","author":"Xu","year":"2025","journal-title":"Cytokine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3164\/jcbn.13-18","article-title":"Changes of energy metabolism, nutritional status and serum cytokine levels in patients with Crohn's disease after anti-tumor necrosis factor-\u03b1 therapy","volume":"53","author":"Nishida","year":"2013","journal-title":"J Clin Biochem Nutr"},{"key":"B28","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11306-022-01932-5","article-title":"Glutathione, polyamine, and lysophosphatidylcholine synthesis pathways are associated with circulating pro-inflammatory cytokines","volume":"18","author":"Liu","year":"2022","journal-title":"Metabolomics"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-014-1825-9","article-title":"L-Arginine and its metabolites in kidney and cardiovascular disease","volume":"46","author":"Popolo","year":"2014","journal-title":"Amino Acids"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/nu7031426","article-title":"Arginine and citrulline and the immune response in sepsis","volume":"7","author":"Wijnands","year":"2015","journal-title":"Nutrients"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1039\/c7fo00465f","article-title":"Modulatory effects of arginine, glutamine and branched-chain amino acids on heat shock proteins, immunity and antioxidant response in exercised rats","volume":"8","author":"Moura","year":"2017","journal-title":"Food Funct"},{"key":"B32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.nut.2017.11.015","article-title":"Effects of short-term dietary restriction and glutamine supplementation in vitro on the modulation of inflammatory properties","volume":"48","author":"C de Oliveira","year":"2018","journal-title":"Nutrition"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.0c06095","article-title":"L-Arginine and L-lysine alleviate myosin from oxidation: their role in maintaining myosin's emulsifying properties","volume":"69","author":"Zhang","year":"2021","journal-title":"J Agric Food Chem"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10010085","article-title":"Oxidative stress and antioxidant nanotherapeutic approaches for inflammatory bowel disease","volume":"10","author":"Liu","year":"2021","journal-title":"Biomedicines"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2020.06.006","article-title":"Oxidative stress and redox-modulating therapeutics in inflammatory bowel disease","volume":"26","author":"Bourgonje","year":"2020","journal-title":"Trends Mol Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01882","article-title":"Control of gut inflammation by modulation of purinergic signaling","volume":"11","author":"Vuerich","year":"2020","journal-title":"Front Immunol"}],"container-title":["Frontiers in Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1867424\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:28:15Z","timestamp":1784780895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1867424\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":36,"alternative-id":["10.3389\/fgstr.2026.1867424"],"URL":"https:\/\/doi.org\/10.3389\/fgstr.2026.1867424","relation":{},"ISSN":["2813-1169"],"issn-type":[{"value":"2813-1169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"1867424"}}